AxoGen, Inc.
AxoGen, Inc. (0HKD.L) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for AxoGen, Inc. (0HKD.L), featuring income statements, balance sheets, and cash flow data.
AxoGen, Inc. (0HKD.L) Income Statement & Financial Overview
Access detailed annual and quarterly income data for AxoGen, Inc. 0HKD.L financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $48.56M | $49.41M | $48.64M | $47.91M |
| Cost of Revenue | $13.63M | $11.83M | $12.21M | $12.57M |
| Gross Profit | $34.93M | $37.58M | $36.44M | $35.34M |
| Gross Profit Ratio | $0.72 | $0.76 | $0.75 | $0.74 |
| R&D Expenses | $6.09M | $6.73M | $7.00M | $6.66M |
| SG&A Expenses | $30.50M | $28.85M | $29.76M | $29.11M |
| Operating Expenses | $36.59M | $35.56M | $36.75M | $35.77M |
| Total Costs & Expenses | $50.22M | $47.39M | $48.96M | $48.34M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $2.25M | $1.80M | $1.89M | $2.19M |
| Depreciation & Amortization | $1.88M | $1.92M | $1.97M | $2.06M |
| EBITDA | $298000.00 | $4.17M | $2.00M | $2.32M |
| EBITDA Ratio | $0.006 | $0.08 | $0.04 | $0.05 |
| Operating Income | -$1.66M | $2.02M | -$316000.00 | -$428000.00 |
| Operating Income Ratio | -$0.03 | $0.04 | -$0.006 | -$0.009 |
| Other Income/Expenses (Net) | -$2.17M | -$1.57M | -$1.54M | -$1.49M |
| Income Before Tax | -$3.83M | $450000.00 | -$1.86M | -$1.92M |
| Income Before Tax Ratio | -$0.08 | $0.009 | -$0.04 | -$0.04 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$3.83M | $450000.00 | -$1.86M | -$1.92M |
| Net Income Ratio | -$0.08 | $0.009 | -$0.04 | -$0.04 |
| EPS | -$0.08 | $0.01 | -$0.04 | -$0.04 |
| Diluted EPS | -$0.08 | $0.009 | -$0.04 | -$0.04 |
| Weighted Avg Shares Outstanding | $45.20M | $44.88M | $43.88M | $43.71M |
| Weighted Avg Shares Outstanding (Diluted) | $45.20M | $48.06M | $43.88M | $43.71M |
Over the last four quarters, AxoGen, Inc.'s revenue moved from $47.91M in Q2 2024 to $48.56M in Q1 2025. Operating income in Q1 2025 was -$1.66M, with a strong operating margin of -3%. Despite fluctuations in R&D and SG&A expenses, EBITDA for AxoGen, Inc. remained robust at $298000.00, reflecting operational efficiency. Net income dropped to -$3.83M, with an EPS of -$0.08. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan